Peptide Initiative

Peptides · Peptide comparison

Orforglipron vs Retatrutide

First oral non-peptide GLP-1 receptor agonist for diabetes and obesity

The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeOrforglipron0.8–17.2 mgRetatrutide4–8 mg
FrequencyOrforglipronOnce dailyRetatrutideOnce weekly
AdministrationOrforglipronoralRetatrutideSubcutaneous injection
Cycle lengthOrforglipronOngoing/indefiniteRetatrutide12+ weeks
Onset speedOrforglipronModerate (1-2 weeks)RetatrutideModerate (1-2 weeks)
Evidence levelOrforglipronStrong human trials (Phase 3 or FDA approved)RetatrutideModerate human trials (Phase 1-2)

Efficacy

Benefit ratings

Weight Management

Orforglipron9%
RetatrutideNo recorded rating

Blood Sugar Control

Orforglipron9%
RetatrutideNo recorded rating

Cardiovascular Health

Orforglipron7%
RetatrutideNo recorded rating

Weight Loss Power

OrforglipronNo recorded rating
Retatrutide98%

Metabolic Health

OrforglipronNo recorded rating
Retatrutide95%

Appetite Control

OrforglipronNo recorded rating
Retatrutide94%

Technical data

Compound specifications

Orforglipron

Molecular formula
C48H48F2N10O5
Molecular weight
883.0 Da
Half-life
About 29–49 hours (elimination half-life after an oral dose)
Bioavailability
77% absolute oral bioavailability (0.8 mg dose); no clinically relevant food effect
CAS number
2212020-52-3

Retatrutide

Molecular formula
C221H342N46O68
Molecular weight
4731 g/mol
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS number
2381089-83-2

Protocols

Dosing compared

Orforglipron

Oral

  • At least 30 days0.8 mg once dailyOnce daily, with or without food · At least 30 daysLabel starting dose. After at least 30 days, increase to 2.5 mg once daily, then after at least 30 more days to 5.5 mg once daily; gradual escalation reduces gastrointestinal reactions [7]. Tablets are swallowed whole, one per day [7].
  • Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mg5.5 mg once dailyOnce daily, with or without food · Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mgFirst maintenance-level dose on the label's escalation [7]. In the phase 3 trial without diabetes, 5.5 mg produced 7.4% average weight loss at 72 weeks against 2.1% on placebo [7].
  • Ongoing; each step after at least 30 days on the previous dose9–17.2 mg once dailyOnce daily, with or without food · Ongoing; each step after at least 30 days on the previous doseOptional further steps of 9 mg, 14.5 mg and 17.2 mg based on response and tolerability; 17.2 mg is the maximum, and 9 mg is the maximum alongside a strong CYP3A4 inhibitor [7]. 17.2 mg produced 11.1% average weight loss at 72 weeks against 2.1% on placebo [7].

Retatrutide

Subcutaneous

  • Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
  • Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
  • Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).

Applications

Best suited for

Orforglipron

Oral GLP-1 receptor agonism without injection burden
Orforglipron is particularly well-suited for individuals focused on oral glp-1 receptor agonism without injection burden. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Weight management in obesity with or without type 2 diabetes
Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Glycemic control in type 2 diabetes as add-on to metformin
Orforglipron is particularly well-suited for individuals focused on glycemic control in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cardiovascular risk reduction through weight loss and metabolic improvements
Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Retatrutide

Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.

Safety profile

Side effects

Orforglipron

Common

  • Nausea
  • Constipation
  • Diarrhea
  • Vomiting

Uncommon

  • Heart Rate Increase

Serious

  • Pancreatitis Risk

Retatrutide

Common

  • Nausea
  • Diarrhea
  • Constipation
  • Decreased appetite

Uncommon

  • Increased heart rate
  • Injection site reactions

Serious

  • Pancreatitis
  • Gallbladder problems

Research status

Safety & evidence

Orforglipron

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use — as FOUNDAYO (orforglipron) tablets, on 1 April 2026, for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition. Not approved for type 2 diabetes.
Safety overview
Orforglipron is FDA approved as FOUNDAYO (April 2026) for long-term weight management. [7][8] Its label carries a boxed warning on thyroid C-cell tumours seen with GLP-1 receptor agonists in rodents — orforglipron itself is not active in rats or mice and caused no rodent tumours — and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. [7] In the two phase 3 weight trials, gastrointestinal reactions affected 60–69% of patients against 37% on placebo, mostly mild or moderate and most frequent during dose escalation; 8% stopped treatment for adverse reactions against 3% on placebo. [7] Labelled warnings also cover acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycaemia with insulin or a sulfonylurea, hypersensitivity, diabetic retinopathy complications, gallbladder disease and pulmonary aspiration under anaesthesia. [7]

Contraindications

  • Personal or family history of medullary thyroid carcinoma (boxed-warning contraindication) [7]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [7]
  • Known hypersensitivity to orforglipron or excipients [7]
  • History of pancreatitis (use with caution)

Retatrutide

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pregnancy or planning to become pregnant
  • History of severe pancreatitis
  • Known allergy to GLP-1 receptor agonists

Decision guide

Which is right for you?

Orforglipron

Choose Orforglipron if…

  • Oral GLP-1 receptor agonism without injection burden
  • Weight management in obesity with or without type 2 diabetes
  • Glycemic control in type 2 diabetes as add-on to metformin
  • Cardiovascular risk reduction through weight loss and metabolic improvements

Retatrutide

Choose Retatrutide if…

  • Significant weight loss
  • Type 2 diabetes management
  • Metabolic health improvement
  • Body composition optimization